Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways ...

纽约/伦敦 - 生物技术公司 Compass Pathways plc (NASDAQ:CMPS) 周二宣布与全国性介入精神病学实践网络Radial Health, Inc.建立战略合作关系，这标志着其第七个此类合作伙伴关系。据 InvestingPro 数据显示，这家市值约6.3亿美元的生物技术公司在过去六个月内股价飙升超过101%。

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June To date, the COMP005 trial is the largest, ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways has entered its seventh U.S. strategic collaboration with Radial Health. Radial Health operates in five ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...

Investing.com - Stifel在 Compass Pathways (NASDAQ:CMPS) 举办其COMP360裸盖菇治疗投资者活动后，重申了"买入"评级和11.00美元的目标价。目前7.82美元的股价较Stifel的目标价有41%的上涨空间，而 InvestingPro 数据显示，该股交易价接近其52周高点7.87美元，过去六个月内实现了126%的价格回报。

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...